Natco Pharma
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services.[4] It is a major producer of branded oncology medicines[5] and hepatitis C drugs.[6] The company specialises in producing complex medicines at affordable prices.[7][8] In 2019, Natco launched its crop health sciences division.[9][10]
 | |
| Type | Public |
|---|---|
| NSE: NATCOPHARM BSE: 524816 | |
| Industry | Pharmaceuticals |
| Founded | 1981 |
| Founder | VC Nannapaneni |
| Headquarters | , India |
Area served | Global |
Key people | VC Nannapaneni (Chairman and MD)[1] Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
| Revenue |  ₹2,811 crore (US$350 million) (FY23)[3] |
| ₹715 crore (US$90 million) (FY23)[3] | |
| Website | natcopharma.co.in |
History
- In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[11]
- In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[6]
- In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[11]
- In 2015, Natco Pharma started production of Sofosbuvir in Nepal.[12]
- In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.[13]
- In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.[14]
- In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[15]
External links
References
- "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
- "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
- "Natco Pharma posts 345% sequential growth in Q4 PAT to ₹276 crore". Mint. 29 May 2023. Retrieved 27 June 2023.
- "Our Business | Natco Pharma". Retrieved 25 April 2022.
- "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
- "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
- PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
- Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
- "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
- Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
- "Niche Play". Business Today. Retrieved 19 April 2020.
- "Natco Pharma History | Natco Pharma Information". The Economic Times. Retrieved 3 February 2022.
- "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
- "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price". Firstpost. 10 May 2017. Retrieved 31 July 2020.
- "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.